Le Lézard
Classified in: Health
Subject: PET

QSM Diagnostics Signs National Distribution Agreement with MWI Animal Health


Agreement will significantly expand the Boston based diagnostics company's channel to bring its products to veterinary clinics throughout the US.

BOSTON, Jan. 11, 2024 /PRNewswire-PRWeb/ -- QSM Diagnostics, a diagnostic device company that helps veterinarians improve their diagnoses and treatment plans to provide better animal care and pet owner satisfaction, has signed a distribution agreement with MWI Animal Health (MWI), a leading provider of state-of-the-art technology solutions and services for veterinary practices, and part of Cencora (formerly AmerisourceBergen).

"We're very excited about the commitment that MWI has made to QSM Diagnostics in the roll out of this new relationship that includes the distribution of our entire line of products," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics.

MWI will inventory, market and promote the QSM Otter and FetchDx products throughout the United States. Through its extensive network of distribution centers, MWI can support efficient deliveries to communities nationwide.

"We're very excited about the commitment that MWI has made to QSM Diagnostics in the roll out of this new relationship that includes the distribution of our entire line of products," says Ed Goluch, Ph.D., Founder and CEO of QSM Diagnostics. "Our mission is to revolutionize how infections are diagnosed and treated. With MWI as a strategic partner, clinics throughout the United States now have access to Otter instruments and FetchDx mail-in kits that help companion animals feel better faster."

QSM's current product lineup includes the Otter eQ, a breakthrough in-clinic diagnostic tool for Pseudomonas measurement, and FetchDx mail-in testing kits, a suite of products which include an animal ear cytology with culture, canine and feline urine culture and sensitivity, and fecal tests.

These kits help veterinarians with:

"We are thrilled to work with QSM Diagnostics to provide veterinarians with access to the company's innovative kits and instruments that will help clinics save time, increase access to care for clients and improve outcomes for patients," said Julia Loew, Senior Vice President for Commercial Operations at MWI Animal Health.

ABOUT QSM DIAGNOSTICS

Boston, Massachusetts-based QSM Diagnostics is fundamentally changing how diagnostic testing is performed. The company's patented technology allows veterinarians to provide better patient treatment and helps mitigate the spread of antimicrobial resistance by making testing faster and easier. QSM's products also increase pet owners' engagement and improve drug administration compliance by educating and involving owners in their pet's health. QSM diagnostics have won multiple animal health industry awards, including the 2021 Animal Health Innovation Award and the 2022 Purina Pet Care Innovation Prize. For more information, please visit https://www.qsmdiagnostics.com.

ABOUT CENCORA:

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at www.cencora.com 

Media Contact

Ed Goluch, QSM Diagnostics, 1 617-579-2004, [email protected], https://qsmdiagnostics.com/

Anne Laffin, Fin Marketing Management, 1 2038681470, [email protected], https://www.finmarketingm.com/

SOURCE QSM Diagnostics


These press releases may also interest you

at 16:11
A new partnership between the Registered Nurses' Association of Ontario (RNAO) and the Indigenous Primary Health Care Council (IPHCC) aims to build a reciprocal relationship that fosters Indigenous representation at decision-making tables within RNAO...

at 16:10
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...

at 16:10
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the...

at 16:10
CareDx, Inc. ? The Transplant Companytm ? a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ? today...

at 16:10
Exicure, Inc. , has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force,...

at 16:05
Axonics, Inc. today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15tm recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive...



News published on and distributed by: